Please select the option that best describes you:
What are your top takeaways in Gynecologic Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
Answer from: at Community Practice
1. ATHENA (LBA5500)- Consistent efficacy signal with PARPi maintenance therapy in the front line- Another potential option for our patients with greater dosing flexibility- The BICR PFS difference in the HRP population really caught my attention. Nearly a 6 month improvement with median PFS in the r...
Sign in or Register to read more
Answer from: at Community Practice
ASCO 2022 for Gynecologic Oncology had many great presentations. Data from the following 3 trials are all likely practice-changing, particularly the ATHENA-MONO trial. This study reaffirms the pivotal role PARPis play in maintenance therapy after first-line platinum-based chemotherapy in ovarian can...